Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62,933,385
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
9,605,170
-
Shares change
-
-739,446
-
Total reported value, excl. options
-
$24,586,580
-
Value change
-
-$3,314,110
-
Number of buys
-
34
-
Number of sells
-
21
-
Price
-
$2.56
Institutional Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q2 2023
As of 30 Jun 2023 Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) had 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 9,605,170 shares of stock of the company.
Largest 10 holders included Laurion Capital Management LP, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Tekla Capital Management LLC, HHLR ADVISORS, LTD., BRIDGEWAY CAPITAL MANAGEMENT, LLC, BlackRock Inc., ExodusPoint Capital Management, LP, RENAISSANCE TECHNOLOGIES LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 63 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.